Spreadsheet: 6646397e-d44e-4ec7-af4c-59f1e77d2efc
Sheet: Sheet1

SUPPLEMENTARY TABLE 1 (Sheet 1): Scores assigned to each of the 154 research questions by technical experts. | Unnamed: 1 | Unnamed: 2 | Unnamed: 3 | Unnamed: 4 | Unnamed: 5 | Unnamed: 6 | Unnamed: 7 | Unnamed: 8 | Unnamed: 9 | Unnamed: 10 | Unnamed: 11 | Unnamed: 12 | Unnamed: 13 | Unnamed: 14 | Unnamed: 15 | Unnamed: 16 | Unnamed: 17 | Unnamed: 18 | Unnamed: 19 | Unnamed: 20 | Unnamed: 21 | Unnamed: 22 | Unnamed: 23 | Unnamed: 24 | Unnamed: 25 | Unnamed: 26 | Unnamed: 27 | Unnamed: 28 | Unnamed: 29 | Unnamed: 30 | Unnamed: 31 | Unnamed: 32 | Unnamed: 33 | Unnamed: 34 | Unnamed: 35 | Unnamed: 36 | Unnamed: 37 | Unnamed: 38 | Unnamed: 39 | Unnamed: 40 | Unnamed: 41 | Unnamed: 42 | Unnamed: 43 | Unnamed: 44 | Unnamed: 45 | Unnamed: 46 | Unnamed: 47 | Unnamed: 48 | Unnamed: 49 | Unnamed: 50 | Unnamed: 51 | Unnamed: 52 | Unnamed: 53 | Unnamed: 54 | Unnamed: 55 | Unnamed: 56 | Unnamed: 57 | Unnamed: 58 | Unnamed: 59 | Unnamed: 60 | Unnamed: 61 | Unnamed: 62 | Unnamed: 63 | Unnamed: 64 | Unnamed: 65 | Unnamed: 66 | Unnamed: 67 | Unnamed: 68 | Unnamed: 69 | Unnamed: 70 | Unnamed: 71 | Unnamed: 72 | Unnamed: 73 | Unnamed: 74 | Unnamed: 75 | Unnamed: 76 | Unnamed: 77 | Unnamed: 78 | Unnamed: 79 | Unnamed: 80 | Unnamed: 81 | Unnamed: 82 | Unnamed: 83 | Unnamed: 84 | Unnamed: 85 | Unnamed: 86 | Unnamed: 87 | Unnamed: 88 | Unnamed: 89 | Unnamed: 90 | Unnamed: 91 | Unnamed: 92
. |  |  |  |  | Q.1.1. Would you say the research question is clear and has well defined endpoints? |  |  |  |  | Q.1.2. Based on: (i) the level of research capacity required to conduct the proposed research; and (ii) the size of the gap from current level of knowledge to the proposed endpoints; would you say that a study can be designed to answer the research question and to reach the proposed endpoints of the research? |  |  |  |  | [NAME]. Do you think that a study needed to answer the proposed research question would obtain ethical approval without major concerns? |  |  |  |  | Q.2.1. Based on the best existing evidence and knowledge, would the intervention(s) which would eventually benefit from the proposed research be efficacious in reducing diarrhoea-related mortality? |  |  |  |  |  | Q.2.2. Based on the best existing evidence and knowledge, would the intervention(s) which would eventually benefit from the proposed research be likely to be effective under programme conditions? |  |  |  |  |  | Q.2.3. Would you say that the evidence upon which your opinion is based is of high quality? |  |  |  |  |  | Q.3.1. Taking into account (i) the infrastructure and resources required to deliver effective interventions (e.g. human resources, health facilities, communication and transport infrastructure), and (ii) the need for change in demand, beliefs and attitudes of users, would you say that the endpoints of the research would be deliverable (or the findings of this research would improve deliverability of other interventions)? |  |  |  |  | Q.3.2. Taking into account the resources available to implement the research results, would you say that the endpoints of the research would be affordable (or improve affordability) within the context of interest? |  |  |  |  | Q.3.3. Taking into account (i) the capacity of the government (e.g. adequacy of government regulation, monitoring and enforcement; governmental intersectoral coordination), and (ii) internal and external partnership required for delivery of interventions (e.g. partnership with civil society and external donor agencies), would you say that the endpoints of the research would be sustainable (or would improve sustainability of other interventions) ? |  |  |  |  | Q.4.1. Taking into account the best available information, would you say that reaching of research endpoints would eventually, assuming high deliverability, affordability and sustainability of health interventions, have a capacity to directly and indirectly remove 5% of all child deaths? |  |  |  |  | Q.4.2. To remove 10% of all child deaths? |  |  |  |  | [NAME]. To remove 15% of all child deaths? |  |  |  |  | Q.5.1. In given context, would you say that the present distribution of disease burden primarily addressed by the proposed research affects mainly the underprivileged in the population? |  |  |  |  | Q.5.2. Would you agree that the immediate results of the proposed research could be of help to all segments of the society, and not just the privileged ones? |  |  |  |  | Q.5.3. Would you say that the proposed research has the overall potential to improve equity in disease burden distribution in the longer term (e.g. by 2015)?
 |  |  | DIARRHOEA
 |  |  |  |  | Duggan | [NAME] | Shantosh. | Snyder | Fontaine | Duggan | [NAME] | Shantosh. | Snyder | Fontaine | Duggan | [NAME] | Shantosh. | Snyder | Fontaine | Bhatnagar | [NAME] | Martines | [NAME] | Vargas | Rollins | Bhatnagar | [NAME] | Martines | [NAME] | Vargas | Rollins | Bhatnagar | [NAME] | Martines | [NAME] | Vargas | Rollins | Bhatnagar | Martines | [NAME] | Salam | Vargas | Bhatnagar | Martines | [NAME] | Salam | Vargas | Bhatnagar | Martines | [NAME] | Salam | Vargas | Duggan | Rollins | Rudan | Fontaine | Pinto | Duggan | Rollins | Rudan | Fontaine | Pinto | Duggan | Rollins | Rudan | Fontaine | Pinto | Salam | Shantosh. | Snyder | Rudan | Pinto | Salam | Shantosh. | Snyder | Rudan | Pinto | Salam | Shantosh. | Snyder | Rudan | Pinto
[NAME] | RESEARCH AVENUE | RESEARCH OPTION | [NAME] | [NAME] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Res. Opt. | ANSWER | EFFECTIV | [NAME] | BURDEN | EQUITY | TOTAL (unwgh) | TOTAL (weigh)
Basic epidemiological research | Measuring the burden | Measuring the burden of acute diarrhoea | What is the incidence of bacterial and viral diarrhoeas? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 |  | What is the incidence of bacterial and viral diarrhoeas? | 1 | 96.66666666666667 | 77.77777777777779 | 75 | 50 | 90 | 77.88888888888889 | 73.71301469066832
 |  |  | What is the incidence of cryptosporidium infection among children <5y, in countries with high burden of HIV/AIDS? | 2 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0.5 | 0.5 | 1 | 1 | 0 |  | 1 |  | 1 | 0 |  | 1 |  | 1 | 0 |  | 0.5 |  | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 0 | 0 |  | What is the incidence of cryptosporidium infection among children <5y, in countries with high burden of HIV/AIDS? | 2 | 90 | 44.44444444444444 | 61.11111111111111 | 6.666666666666667 | 53.33333333333334 | 51.11111111111111 | 44.54583074694806
 |  |  | What is the prevalence of rotavirus genotypes? | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 0.5 |  | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |  | What is the prevalence of rotavirus genotypes? | 3 | 100 | 69.44444444444444 | 70.83333333333334 | 43.33333333333334 | 80 | 72.72222222222223 | 68.41661493896132
 |  |  | What is the prevalence of coronavirus genotypes? | 4 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0 |  | 1 | 0.5 | 0 | 1 | 0 |  | 0 | 0 | 0 | 1 | 0.5 |  | 1 | 0 | 1 | 0.5 |  | 0.5 | 0 | 1 | 1 |  | 0.5 | 0 | 1 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |  | 0.5 | 1 | 0 | 0 | 1 | 0.5 | 1 | 0 | 0 | 0.5 | 0 | 0 |  | What is the prevalence of coronavirus genotypes? | 4 | 80 | 43.33333333333334 | 58.33333333333334 | 0 | 39.28571428571428 | 44.19047619047619 | 37.5667287399131
 |  |  | What is the prevalence of norovirus genotypes? | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |  | 1 | 1 | 0 | 1 | 0 |  | 0 | 1 | 0 | 1 | 0.5 |  | 1 | 0 | 1 | 0.5 |  | 0.5 | 0 | 1 | 1 |  | 0.5 | 0 | 1 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 |  | 0.5 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 0.5 | 0 | 0 |  | What is the prevalence of norovirus genotypes? | 5 | 100 | 56.66666666666666 | 58.33333333333334 | 0 | 50 | 53 | 45.09310986964618
 |  |  | How much more resource would it take for the rotavirus surveillance network to look for other bacterial or viral agents? | 6 | 1 | 0.5 |  | 1 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 1 |  | 1 | 1 | 1 | 0.5 | 0 |  | 0 | 0 | 1 | 0.5 | 0 |  | 0 | 0 | 1 | 0.5 | 0 |  | 0.5 | 0 | 1 | 0 |  |  | 0.5 | 1 | 0 |  |  | 0.5 | 1 | 0 |  |  | 0.5 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |  |  | 1 | 1 | 1 |  |  | 1 | 0.5 | 1 |  |  | 1 | 0.5 | 0 |  | How much more resource would it take for the rotavirus surveillance network to look for other bacterial or viral agents? | 6 | 91.66666666666666 | 33.33333333333333 | 23.68421052631579 | 26.66666666666667 | 77.77777777777779 | 50.62573099415205 | 47.52142616006185
 |  | Measuring the burden of persistent diarrhoea | What is the incidence of persistent diarrhoea among urban and rural populations? | 7 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0.5 | 1 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | What is the incidence of persistent diarrhoea among urban and rural populations? | 7 | 100 | 77.77777777777779 | 66.66666666666666 | 50 | 83.33333333333334 | 75.55555555555557 | 71.79805503827849
 |  |  | What is the prevalence of persistent diarrhoea in corelation with the prevalence of malnutrition, vitamin A deficiency and zinc status? | 8 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 0 | 0 | 0 | 0.5 | 0.5 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 |  | What is the prevalence of persistent diarrhoea in corelation with the prevalence of malnutrition, vitamin A deficiency and zinc status? | 8 | 83.33333333333334 | 77.77777777777779 | 73.33333333333333 | 50 | 73.33333333333333 | 71.55555555555556 | 68.22884336850818
 |  | Measuring the burden of dysentery | What are the incidences of Shigella infections by serotypes among children <5y in different regions? | 9 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 0.5 |  | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | What are the incidences of Shigella infections by serotypes among children <5y in different regions? | 9 | 100 | 47.22222222222222 | 70.83333333333334 | 6.666666666666667 | 90 | 62.94444444444444 | 54.60324849989654
 |  |  | What is the incidence of multi-resistant Shigella infection among children < 5y in different regions? | 10 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0.5 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0.5 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 0.5 |  | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |  | What is the incidence of multi-resistant Shigella infection among children < 5y in different regions? | 10 | 100 | 52.77777777777778 | 66.66666666666666 | 10 | 86.66666666666667 | 63.22222222222221 | 55.32381543554728
 |  |  | Assess rapid diagnostic procedures (i.e. commercial production of antibody against serotypes) to allow the determination of the actual burden of shigellosis. | 11 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0.5 | 1 | 0 |  | 1 | 0.5 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 1 | 0 |  | Assess rapid diagnostic procedures (i.e. commercial production of antibody against serotypes) to allow the determination of the actual burden of shigellosis. | 11 | 80 | 50 | 75 | 6.666666666666667 | 76.66666666666667 | 57.66666666666666 | 49.90378646803228
 |  |  | Assess rapid diagnostic procedures for the detection of antibiotic multi-resistant strains of Shigella. | 12 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0.5 | 0 | 1 | 0 | 0 | 1 | 0.5 | 1 | 0.5 |  | 1 | 0 | 0.5 | 0.5 |  | 1 | 0 | 1 | 0.5 |  | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 0.5 | 0 | 0.5 | 0.5 | 1 | 1 | 0 |  | Assess rapid diagnostic procedures for the detection of antibiotic multi-resistant strains of Shigella. | 12 | 86.66666666666667 | 44.44444444444444 | 58.33333333333334 | 6.666666666666667 | 60 | 51.22222222222221 | 44.61928408855783
 |  |  | Estimate the morbidity and mortality associated with different serotypes of  Shigella. | 13 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0.5 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 0.5 |  | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 |  | Estimate the morbidity and mortality associated with different serotypes of  Shigella. | 13 | 86.66666666666667 | 52.77777777777778 | 66.66666666666666 | 3.333333333333333 | 80 | 57.88888888888889 | 49.63790606248706
 |  | HIV-related diarrhoea | What is the incidence of HIV-related diarrhoeal disease? | 14 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0.5 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0.5 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 0 |  | What is the incidence of HIV-related diarrhoeal disease? | 14 | 93.33333333333333 | 58.33333333333334 | 70 | 23.33333333333333 | 46.66666666666666 | 58.33333333333334 | 53.14090626939789
 |  |  | What are the enteric pathogens most commonly associated with diarrhoea among HIV-infected and AIDS children? | 15 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0 | 1 | 0.5 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 0 |  | What are the enteric pathogens most commonly associated with diarrhoea among HIV-infected and AIDS children? | 15 | 100 | 69.44444444444444 | 76.66666666666667 | 26.66666666666667 | 50 | 64.55555555555557 | 58.8681978067453
 | Understanding risk factors | Diarrhoea (acute and persistent) | What is the relative risk of partial breastfeeding and non-breastfeeding, malnutrition, micronutrient deficiencies (vitamin A and zinc), low birth weight on the prevalence/incidence of diarrhoea? | 16 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 0.5 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 |  | What is the relative risk of partial breastfeeding and non-breastfeeding, malnutrition, micronutrient deficiencies (vitamin A and zinc), low birth weight on the prevalence/incidence of diarrhoea? | 16 | 83.33333333333334 | 77.77777777777779 | 73.33333333333333 | 66.66666666666666 | 80 | 76.22222222222221 | 74.7899855162425
 |  |  | What are the maternal care-taking behaviours (safe disposal of faeces, hand washing practices, etc.) that have an impact on the prevalence/incidence of  diarrhoea? | 17 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | What are the maternal care-taking behaviours (safe disposal of faeces, hand washing practices, etc.) that have an impact on the prevalence/incidence of  diarrhoea? | 17 | 100 | 77.77777777777779 | 66.66666666666666 | 40 | 96.66666666666667 | 76.22222222222223 | 70.7986757707428
 |  |  | What are the environmental risk factors for diarrhoea? | 18 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0.5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | What are the environmental risk factors for diarrhoea? | 18 | 100 | 83.33333333333334 | 66.66666666666666 | 40 | 83.33333333333334 | 74.66666666666667 | 69.42892613283675
 |  |  | What is the micronutrient status of children hospitalized with diarrhoea, in comparison with that of the general population? | 19 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0 | 0.5 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |  | What is the micronutrient status of children hospitalized with diarrhoea, in comparison with that of the general population? | 19 | 83.33333333333334 | 94.11764705882352 | 60 | 20 | 80 | 67.49019607843137 | 59.98904589768868
 |  |  | What are the best indicators to assess the micronutrient status of children? | 20 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 0 | 0.5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |  | What are the best indicators to assess the micronutrient status of children? | 20 | 90 | 88.88888888888889 | 63.33333333333333 | 36.66666666666666 | 86.66666666666667 | 73.11111111111111 | 67.45706600455203
 |  | Dysentery | What is the impact of malnutrition, younger age, breastfeeding, measles, and vitamin A and zinc status on the incidence/prevalence of shigellosis? | 21 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 |  | What is the impact of malnutrition, younger age, breastfeeding, measles, and vitamin A and zinc status on the incidence/prevalence of shigellosis? | 21 | 80 | 72.22222222222221 | 73.33333333333333 | 36.66666666666666 | 80 | 68.44444444444444 | 63.52782950548313
 |  |  | What is the impact of unsafe water supply, poor sanitation and hygiene for shigellosis? | 22 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | What is the impact of unsafe water supply, poor sanitation and hygiene for shigellosis? | 22 | 76.66666666666667 | 75 | 73.33333333333333 | 23.33333333333333 | 93.33333333333333 | 68.33333333333334 | 61.2911235257604
 |  |  | What are the methods of transmission of multi-resistant strains of Shigella? | 23 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 1 |  | 1 |  | 1 | 0 |  |  | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | What are the methods of transmission of multi-resistant strains of Shigella? | 23 | 76.66666666666667 | 75 | 60 | 6.666666666666667 | 83.33333333333334 | 60.33333333333334 | 51.95530726256983
 |  |  | Determine the mechanisms of multi-resistance in strains of Shigella (chromosomal or non-chromosomal)? | 24 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 |  | 1 |  | 1 | 0 |  | 0 | 0.5 | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |  | Determine the mechanisms of multi-resistance in strains of Shigella (chromosomal or non-chromosomal)? | 24 | 85.71428571428571 | 50 | 45.83333333333333 | 3.333333333333333 | 66.66666666666666 | 50.30952380952381 | 43.31049924625344
 | Evaluating the existing interventions | Diarrhoea | Is the reduction in mortality due to diarrhoea due to lower incidence, or to reduced incidence of malnutrition, or to better treatment? | 25 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 |  | 1 |  | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |  | Is the reduction in mortality due to diarrhoea due to lower incidence, or to reduced incidence of malnutrition, or to better treatment? | 25 | 80 | 84.375 | 60 | 63.33333333333333 | 56.66666666666666 | 68.875 | 68.00046554934823
 |  | Water and Sanitation | Assess the efficacy of intervention like safe water in the communities to reduce diarrhoeal disease incidence, including Shigella infection. | 26 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 0 | 0 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Assess the efficacy of intervention like safe water in the communities to reduce diarrhoeal disease incidence, including Shigella infection. | 26 | 93.33333333333333 | 86.11111111111111 | 76.66666666666667 | 16.66666666666666 | 93.33333333333333 | 73.22222222222223 | 64.42996068694393
 |  | Zinc supplementation | What is the effectiveness of zinc supplementation on the outcome and incidence of diarrhoea in the community? | 27 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | What is the effectiveness of zinc supplementation on the outcome and incidence of diarrhoea in the community? | 27 | 100 | 97.22222222222221 | 93.33333333333333 | 70 | 100 | 92.11111111111111 | 88.67370163459549
 |  | Reduced osmolarity ORS | What is the acceptability and effectiveness of the new reduced osmolarity ORS in clinic as well as in the community? | 28 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |  | What is the acceptability and effectiveness of the new reduced osmolarity ORS in clinic as well as in the community? | 28 | 100 | 83.33333333333334 | 100 | 80 | 93.33333333333333 | 91.33333333333334 | 89.68342644320298
 |  | ORS | What are the barriers against appropriate use of ORT? | 29 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |  | What are the barriers against appropriate use of ORT? | 29 | 86.66666666666667 | 88.88888888888889 | 100 | 76.66666666666667 | 93.33333333333333 | 89.11111111111111 | 87.10324849989655
 |  | HIV infection and diarrhoea | What is the impact of the ARV therapy on the burden of diarrhoeal disease? | 30 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0.5 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 |  | 1 | 0.5 | 0 | 0 | 1 |  | 0.5 | 0 | 0.5 | 0 | 0 |  | 1 | 1 | 0 | 1 | 0 |  | 1 | 0 |  | 0.5 |  | 1 | 0 |  | 0 |  | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 0.5 | 0 | 0 | 0.5 | 1 | 0 | 1 | 0 | 0.5 | 1 | 0.5 | 1 |  | What is the impact of the ARV therapy on the burden of diarrhoeal disease? | 30 | 63.33333333333333 | 46.66666666666666 | 45 | 26.66666666666667 | 50 | 46.33333333333333 | 43.41713221601489
 |  | Rotavirus vaccine programmes | Determine the relationship between vaccine coverage and vaccine protection | 31 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |  | Determine the relationship between vaccine coverage and vaccine protection | 31 | 80 | 69.44444444444444 | 90 | 50 | 83.33333333333334 | 74.55555555555557 | 70.75522449824125
 |  |  | What is the prevalence of rotavirus genotypes among vaccinated and non-vaccinated children? | 32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 |  | 1 |  | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 0 |  | What is the prevalence of rotavirus genotypes among vaccinated and non-vaccinated children? | 32 | 100 | 78.125 | 73.33333333333333 | 50 | 80 | 76.29166666666666 | 72.39369956548727
 |  |  | Is the protective efficacy of rotavirus vaccine different in malnourished children  than th eone observed in well-nourished children, and if so what is its implication for mass vaccination programmes? | 33 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | Is the protective efficacy of rotavirus vaccine different in malnourished children  than th eone observed in well-nourished children, and if so what is its implication for mass vaccination programmes? | 33 | 86.66666666666667 | 79.41176470588235 | 66.66666666666666 | 46.66666666666666 | 86.66666666666667 | 73.2156862745098 | 69.15470843831015
Health Policy and System Research | Studying system capacity to reduce exposure to proven health risks | Enhancement of health worker-mother encounter to identify children exposed to proven risks | Develop and test a health worker/community workers-friendly, effective algorithm/method for identification of children at risk for recurring and/or persistent diarrhoea | 34 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Develop and test a health worker/community workers-friendly, effective algorithm/method for identification of children at risk for recurring and/or persistent diarrhoea | 34 | 80 | 80.55555555555556 | 76.66666666666667 | 53.33333333333334 | 100 | 78.11111111111111 | 74.23546451479413
 |  | HPSR to assess capacity of health system to detect pathogens and their risk factors | Assess coverage of existing community and hospital based methods to detect risk exposure | 35 | 0 | 0.5 | 0.5 | 0 | 0 | 0.5 | 0.5 | 0.5 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0.5 | 1 | 1 | 0 |  | 1 | 0 | 0 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 |  | Assess coverage of existing community and hospital based methods to detect risk exposure | 35 | 50 | 58.82352941176471 | 73.33333333333333 | 16.66666666666666 | 73.33333333333333 | 54.4313725490196 | 48.37149012305108
 |  |  | Assess coverage of existing facility-based methods of diagnosis of  diarrhoea pathogens. | 36 | 1 | 0.5 | 0.5 | 0 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 |  | Assess coverage of existing facility-based methods of diagnosis of  diarrhoea pathogens. | 36 | 63.33333333333333 | 58.33333333333334 | 76.66666666666667 | 3.333333333333333 | 73.33333333333333 | 55 | 46.88392302917442
 |  | HPSR to assess capacity of health system to administer zinc with ORS in the treatment of diarrhoea | Assess coverage of existing community and hospital based methods to treat all episodes of diarrhoea with zinc and ORS | 37 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0 |  | 1 | 0 | 0 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |  | Assess coverage of existing community and hospital based methods to treat all episodes of diarrhoea with zinc and ORS | 37 | 83.33333333333334 | 70.58823529411765 | 80 | 53.33333333333334 | 93.33333333333333 | 76.11764705882352 | 72.65783035746887
 |  | Safe water | Determine methods used for provision of safe water for drinking, preparing food, and cooking purposes | 38 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | Determine methods used for provision of safe water for drinking, preparing food, and cooking purposes | 38 | 93.33333333333333 | 80.55555555555556 | 73.33333333333333 | 26.66666666666667 | 93.33333333333333 | 73.44444444444444 | 66.24663769915166
 |  | Food borne illness | Develop and test interventions to promote safe food handling. | 39 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | Develop and test interventions to promote safe food handling. | 39 | 86.66666666666667 | 80.55555555555556 | 66.66666666666666 | 20 | 90 | 68.77777777777779 | 61.21249741361473
 | Studying system capacity to deliver efficacious interventions | HPSR on breastfeeding and nutrition | Develop and evaluate interventions to increase % of early initiation of breast feeding and exclusively breastfed infants up to 6 months of age. | 40 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 0.5 | 0.5 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Develop and evaluate interventions to increase % of early initiation of breast feeding and exclusively breastfed infants up to 6 months of age. | 40 | 90 | 97.22222222222221 | 83.33333333333334 | 70 | 93.33333333333333 | 86.77777777777777 | 84.09890337264638
 |  | HPSR on nutrition | Health policy, systems, and education/behaviour modification research to increase % of infants and children <2 who are breast fed. | 41 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0.5 | 0 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | Health policy, systems, and education/behaviour modification research to increase % of infants and children <2 who are breast fed. | 41 | 70 | 86.11111111111111 | 73.33333333333333 | 76.66666666666667 | 83.33333333333334 | 77.88888888888889 | 77.56465963169875
 |  |  | Monitor implementation of the Milk Code, and the barriers to its implementation | 42 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 0 |  | 1 | 0 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 0.5 |  | 1 | 0.5 | 0.5 | 0.5 | 0 | 0 | 1 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0 | 0 |  | 0 | 1 |  | Monitor implementation of the Milk Code, and the barriers to its implementation | 42 | 86.66666666666667 | 80 | 66.66666666666666 | 16.66666666666666 | 50 | 60 | 53.25884543761639
 |  |  | Measure initiation and exclusivity of breastfeeding among BFHI hospitals | 43 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 0.5 |  | 1 | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 1 |  | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 1 | 1 | 1 | 0.5 | 0 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 0.5 |  | Measure initiation and exclusivity of breastfeeding among BFHI hospitals | 43 | 100 | 90 | 75 | 33.33333333333333 | 66.66666666666666 | 73 | 66.88081936685288
 |  |  | Determine problems and barriers to effective promotion of breastfeeding among BFHI hospitals | 44 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 0.5 |  | 1 | 0 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 1 |  | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 0.5 |  | Determine problems and barriers to effective promotion of breastfeeding among BFHI hospitals | 44 | 100 | 83.33333333333334 | 75 | 36.66666666666666 | 73.33333333333333 | 73.66666666666667 | 68.02917442582248
 |  |  | Identify cost-effective, sustainable methods for community-based promotion and support for early initiation and continuation of breastfeeding during first 6 months of life and prolonged breastfeeding | 45 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | Identify cost-effective, sustainable methods for community-based promotion and support for early initiation and continuation of breastfeeding during first 6 months of life and prolonged breastfeeding | 45 | 86.66666666666667 | 88.88888888888889 | 86.66666666666667 | 76.66666666666667 | 90 | 85.77777777777779 | 84.3285743844403
 |  |  | Formulation of locally adapted policies and guidelines to strengthen implementation of the Milk Code | 46 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |  | 1 | 1 | 1 | 1 | 0.5 |  | 0.5 | 1 | 1 | 1 | 0 |  | 1 | 0 | 0 | 1 | 1 |  | 0.5 | 1 | 1 | 0.5 |  | 1 | 0.5 | 1 | 0.5 |  | 1 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0.5 | 1 | 0,.5 | 0 | 1 | 0.5 | 1 |  | Formulation of locally adapted policies and guidelines to strengthen implementation of the Milk Code | 46 | 73.33333333333333 | 73.33333333333333 | 66.66666666666666 | 10 | 60 | 56.66666666666666 | 49.32960893854748
 |  |  | Education/behaviour modification research to increase energy density of weaning foods at the household level (in areas with food availability). | 47 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 0.5 | 0.5 |  | Education/behaviour modification research to increase energy density of weaning foods at the household level (in areas with food availability). | 47 | 83.33333333333334 | 88.88888888888889 | 60 | 40 | 70 | 68.44444444444444 | 63.97475687978481
 |  |  | Efficacy / effectiveness studies of interventions to do behaviour modifications to reduce baby bottle utilizations | 48 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 0.5 | 1 | 0 | 0 | 0.5 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 0 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 1 | 0.5 |  | Efficacy / effectiveness studies of interventions to do behaviour modifications to reduce baby bottle utilizations | 48 | 96.66666666666667 | 63.88888888888889 | 73.33333333333333 | 16.66666666666666 | 66.66666666666666 | 63.44444444444444 | 56.39561349058555
 |  |  | Education/behaviour modification research to increase utilization of refrigerators for storage of weaning foods. | 49 | 0 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 |  | 0.5 | 1 | 1 | 0.5 | 1 |  | 0.5 | 1 | 0 | 1 | 0.5 |  | 0 | 0 | 1 | 0.5 | 0 |  | 0.5 | 0 | 0.5 | 0.5 |  | 1 | 0 | 0.5 | 0.5 |  | 0.5 | 0.5 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 1 | 1 | 0 |  | Education/behaviour modification research to increase utilization of refrigerators for storage of weaning foods. | 49 | 70 | 56.66666666666666 | 41.66666666666667 | 0 | 40 | 41.66666666666666 | 35.27312228429548
 |  |  | Efficacy /Cost-Effectiveness studies and education /behaviour modification research to increase consumption of Lactobacillus GG probiotic (impact on morbidity and mortality). | 50 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 0.5 | 0 | 1 | 0 | 0 | 0 | 0.5 | 0 | 1 | 0 | 1 | 0.5 | 0 | 1 | 0.5 |  | 0.5 | 0 | 0.5 | 1 |  | 0.5 | 0 | 1 | 0.5 |  | 0.5 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |  | Efficacy /Cost-Effectiveness studies and education /behaviour modification research to increase consumption of Lactobacillus GG probiotic (impact on morbidity and mortality). | 50 | 83.33333333333334 | 47.22222222222222 | 45.83333333333333 | 6.666666666666667 | 53.33333333333334 | 47.27777777777779 | 41.26681150424167
 |  |  | Efficacy / effectiveness studies of interventions for behaviour modifications to increase potties utilization /improved faeces disposal practices (impact on morbidity and mortality). | 51 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0.5 | 1 | 0 |  | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 0 | 0.5 | 0.5 | 0.5 | 1 | 0 | 1 | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | Efficacy / effectiveness studies of interventions for behaviour modifications to increase potties utilization /improved faeces disposal practices (impact on morbidity and mortality). | 51 | 96.66666666666667 | 35.29411764705883 | 53.33333333333334 | 20 | 86.66666666666667 | 58.3921568627451 | 52.97695987147187
 |  |  | HPSR to generate new knowledge to increase coverage of vitamin A supplementation (to reduce diarrhoea severity and improve mortality). | 52 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | HPSR to generate new knowledge to increase coverage of vitamin A supplementation (to reduce diarrhoea severity and improve mortality). | 52 | 100 | 88.88888888888889 | 76.66666666666667 | 36.66666666666666 | 90 | 78.44444444444444 | 72.01944961721497
 |  | HPSR on utilization and access to ORS and zinc | Determine the problems and barriers against access to ORS packets at all times in all sites for all children who may need it. | 53 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Determine the problems and barriers against access to ORS packets at all times in all sites for all children who may need it. | 53 | 86.66666666666667 | 83.33333333333334 | 80 | 53.33333333333334 | 100 | 80.66666666666666 | 76.42458100558659
 |  |  | Determine the problems and barriers that limit the promotion of and utilization of low osmolarity ORS (effectiveness studies). | 54 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |  | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Determine the problems and barriers that limit the promotion of and utilization of low osmolarity ORS (effectiveness studies). | 54 | 90 | 79.41176470588235 | 100 | 53.33333333333334 | 100 | 84.54901960784312 | 79.70716033154416
 |  |  | Does the health system allow for financial support to deliver zinc supplementation for the treatment of diarrhoea, especially in the public health setting? | 55 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 0 | 1 |  | 1 | 0 | 1 | 1 | 0 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 0.5 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 |  | Does the health system allow for financial support to deliver zinc supplementation for the treatment of diarrhoea, especially in the public health setting? | 55 | 96.66666666666667 | 76.66666666666667 | 100 | 46.66666666666666 | 63.33333333333333 | 76.66666666666667 | 72.07324643078832
 |  |  | How can the private sector be used to strengthen delivery of zinc supplementation? | 56 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 0.5 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 0 | 1 | 0.5 | 1 | 0.5 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 0.5 |  | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 |  | How can the private sector be used to strengthen delivery of zinc supplementation? | 56 | 86.66666666666667 | 63.88888888888889 | 91.66666666666666 | 53.33333333333334 | 80 | 75.11111111111111 | 71.8549555141734
 |  |  | Assess the impact of zinc therapy on the use of ORT by family and community | 57 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Assess the impact of zinc therapy on the use of ORT by family and community | 57 | 90 | 86.11111111111111 | 90 | 33.33333333333333 | 96.66666666666667 | 79.22222222222221 | 72.04014069935856
 |  |  | Assess cost effectiveness of inpatient treatment of diarrhoea with zinc and ORS | 58 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 0 | 1 | 0 | 1 | 1 | 0.5 |  | Assess cost effectiveness of inpatient treatment of diarrhoea with zinc and ORS | 58 | 90 | 94.11764705882352 | 100 | 40 | 63.33333333333333 | 77.49019607843137 | 71.5036331105999
 |  |  | Asses cost effectiveness of outpatient treatment of diarrhoea with zinc and ORS | 59 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0.5 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | Asses cost effectiveness of outpatient treatment of diarrhoea with zinc and ORS | 59 | 93.33333333333333 | 91.17647058823529 | 100 | 66.66666666666666 | 80 | 86.23529411764704 | 83.14309708986015
 |  |  | Assess proportion of cases with diarrhoea who get appropriate inpatient treatment | 60 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 |  | Assess proportion of cases with diarrhoea who get appropriate inpatient treatment | 60 | 90 | 85.29411764705883 | 76.66666666666667 | 43.33333333333334 | 83.33333333333334 | 75.72549019607843 | 70.69887172746195
 |  |  | Assess proportion of cases with diarrhoea who get appropriate outpatient treatment | 61 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 0 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Assess proportion of cases with diarrhoea who get appropriate outpatient treatment | 61 | 86.66666666666667 | 85.29411764705883 | 76.66666666666667 | 73.33333333333333 | 100 | 84.3921568627451 | 82.7038375871764
 |  | HPSR on the management of dysentery | Assess cost-effectiveness of inpatient treatment of severe shigellosis. | 62 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0 | 0 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 1 | 0.5 |  | Assess cost-effectiveness of inpatient treatment of severe shigellosis. | 62 | 86.66666666666667 | 69.44444444444444 | 73.33333333333333 | 10 | 60 | 59.88888888888889 | 52.19532381543554
 |  |  | Assess cost effectiveness of outpatient treatment of shigellosis | 63 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0 | 0 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | Assess cost effectiveness of outpatient treatment of shigellosis | 63 | 86.66666666666667 | 63.88888888888889 | 70 | 20 | 80 | 64.11111111111111 | 57.40120008276433
 |  |  | Determine the proportion of detected cases who get appropriate inpatient treatment | 64 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 1 | 1 |  | 0 | 1 | 0.5 | 0 | 1 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 |  | Determine the proportion of detected cases who get appropriate inpatient treatment | 64 | 86.66666666666667 | 73.52941176470588 | 66.66666666666666 | 20 | 86.66666666666667 | 66.70588235294117 | 59.52240113922664
 |  |  | Determine the proportion of detected cases who get appropriate outpatient treatment | 65 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0.5 | 1 | 1 | 1 |  | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 1 | 1 |  | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0.5 | 0.5 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Determine the proportion of detected cases who get appropriate outpatient treatment | 65 | 86.66666666666667 | 64.70588235294117 | 66.66666666666666 | 40 | 100 | 71.60784313725489 | 66.8864789863804
 |  |  | Assess capacity of the health system and availability of guidelines and information system for promotion of effective antimicrobial therapy and reduce inappropriate antimicrobial therapy | 66 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 1 | 0.5 |  | Assess capacity of the health system and availability of guidelines and information system for promotion of effective antimicrobial therapy and reduce inappropriate antimicrobial therapy | 66 | 86.66666666666667 | 80.55555555555556 | 73.33333333333333 | 46.66666666666666 | 50 | 67.44444444444444 | 64.22925719015103
 |  | HPSR to determine how IMCI can be effectively integrated into the current public health set-up | Test indicators to determine effectiveness of IMCI in treatment of diarrhoea and in term of reducing disease burden. | 67 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 1 | 0 |  | 1 | 0.5 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | Test indicators to determine effectiveness of IMCI in treatment of diarrhoea and in term of reducing disease burden. | 67 | 96.66666666666667 | 83.33333333333334 | 95.83333333333334 | 73.33333333333333 | 80 | 85.83333333333334 | 83.9649286157666
 |  |  | What is the impact of IMCI in different population groups on timely  identification and treatment of acute diarrhoeas? | 68 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | 1 | 0 | 1 | 1 | 0.5 |  | 1 | 0 |  | 1 | 0 |  | 1 | 0.5 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | What is the impact of IMCI in different population groups on timely  identification and treatment of acute diarrhoeas? | 68 | 100 | 67.85714285714286 | 95.83333333333334 | 73.33333333333333 | 93.33333333333333 | 86.07142857142857 | 84.3418018976678
 |  |  | What is the impact of IMCI in different population groups on administration and promotion of zinc therapy for acute and persistent diarrhoeas? | 69 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 |  | 1 |  |  | 1 | 0 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | What is the impact of IMCI in different population groups on administration and promotion of zinc therapy for acute and persistent diarrhoeas? | 69 | 96.66666666666667 | 92.3076923076923 | 95.83333333333334 | 53.33333333333334 | 100 | 87.62820512820512 | 82.27367139378313
 |  |  | Design locally-adapted training programmes to orient health workers on IMCI. | 70 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 0.5 | 0.5 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 0.5 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Design locally-adapted training programmes to orient health workers on IMCI. | 70 | 86.66666666666667 | 90 | 100 | 70 | 100 | 89.33333333333334 | 86.23836126629423
 |  | Rotavirus and [NAME]  vaccination | Community-based trials on rotavirus vaccination– impact, cost-effectiveness, and implementation (coverage) | 71 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 |  | Community-based trials on rotavirus vaccination– impact, cost-effectiveness, and implementation (coverage) | 71 | 93.33333333333333 | 86.11111111111111 | 73.33333333333333 | 43.33333333333334 | 76.66666666666667 | 74.55555555555556 | 69.7434305814194
 |  |  | How to improve coverage or rotavirus vaccine in countries with greatest needs (impact on morbidity and mortality)? | 72 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | How to improve coverage or rotavirus vaccine in countries with greatest needs (impact on morbidity and mortality)? | 72 | 93.33333333333333 | 88.88888888888889 | 80 | 53.33333333333334 | 93.33333333333333 | 81.77777777777777 | 77.37637078419202
 |  |  | How to increase coverage of measles vaccine: eradication? (impact mostly on diarrhoea mortality and some morbidity) | 73 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | How to increase coverage of measles vaccine: eradication? (impact mostly on diarrhoea mortality and some morbidity) | 73 | 93.33333333333333 | 91.66666666666666 | 100 | 20 | 96.66666666666667 | 80.33333333333334 | 70.83798882681563
 |  | Water and Sanitation | Systems and education/behaviour modification research to improve water consumed per person per day. | 74 | 0 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0 | 0 | 0.5 | 0 | 0 | 1 | 0 | 0 | 0 |  | 0.5 | 0.5 | 0 | 0.5 | 0.5 | 0.5 | 1 | 0 | 0.5 | 0.5 | 0 | 0.5 | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 1 | 0.5 |  | Systems and education/behaviour modification research to improve water consumed per person per day. | 74 | 66.66666666666666 | 32.35294117647059 | 40 | 3.333333333333333 | 56.66666666666666 | 39.80392156862744 | 34.41778946215357
 |  |  | System research to measure the effectiveness of piped water on diarrhoea (impact on morbidity and mortality): at the community vs home and Intermittent vs. 24 h availability | 75 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 |  | 1 | 0 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 1 | 1 | 0.5 |  | System research to measure the effectiveness of piped water on diarrhoea (impact on morbidity and mortality): at the community vs home and Intermittent vs. 24 h availability | 75 | 93.33333333333333 | 79.41176470588235 | 66.66666666666666 | 30 | 50 | 63.88235294117646 | 58.70157373936539
 |  |  |  |  |  | 1 |  | 0.5 |  |  | 1 |  | 1 |  |  | 1 |  | 1 |  |  | 1 |  |  |  |  |  | 1 |  |  |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 1 |  |  |  | 0 | 1 |  |  |  | 0 | 1 |  |  |  |  | 76 | 91.66666666666666 |  |  | 0 | 33.33333333333333 | 25 | 22.03600248292985
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  | 0.5 |  |  | 1 |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 1 |  | 0 |  |  | 1 |  | 0 |  |  |  |  |  | 77 | 100 |  |  | 0 | 40 | 28 | 24.65549348230913
 |  |  | Systems and education/behaviour modification research to increase coverage of sewage systems (impact on morbidity and mortality). | 76 | 0.5 | 1 | 0.5 | 0.5 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |  | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 0 | 0.5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 1 | 0.5 |  | Systems and education/behaviour modification research to increase coverage of sewage systems (impact on morbidity and mortality). | 78 | 66.66666666666666 | 73.52941176470588 | 63.33333333333333 | 36.66666666666666 | 66.66666666666666 | 61.37254901960783 | 57.43674005915214
 |  |  | Systems and education/behaviour modification research to increase prevalence of effective latrines (impact on morbidity and mortality). | 77 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |  | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 0.5 |  | Systems and education/behaviour modification research to increase prevalence of effective latrines (impact on morbidity and mortality). | 79 | 90 | 70.58823529411765 | 63.33333333333333 | 30 | 80 | 66.7843137254902 | 61.22393836491766
 |  |  | Health policy, systems, and education/behaviour modification research to increase the proportion of women and children washing their hands effectively improve hand washing promotion. (impact on morbidity and mortality) | 78 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 |  | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0.5 | 0.5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 |  | Health policy, systems, and education/behaviour modification research to increase the proportion of women and children washing their hands effectively improve hand washing promotion. (impact on morbidity and mortality) | 80 | 90 | 82.35294117647058 | 83.33333333333334 | 33.33333333333333 | 76.66666666666667 | 73.13725490196079 | 66.94417059188666
 |  |  | System and community research to reduce costs /improve deliverability and increase coverage of piped water systems (Impact on morbidity and mortality) | 79 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0 | 0 | 0.5 |  | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 |  | System and community research to reduce costs /improve deliverability and increase coverage of piped water systems (Impact on morbidity and mortality) | 81 | 96.66666666666667 | 79.41176470588235 | 66.66666666666666 | 46.66666666666666 | 76.66666666666667 | 73.2156862745098 | 69.24781830795631
Research to improve existing interventions | Research to improve deliverability of existing interventions | Zinc supplementation | What is the acceptability/adherence to zinc supplementation for the management of diarrhoea in various settings (urban, rural)? | 80 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | What is the acceptability/adherence to zinc supplementation for the management of diarrhoea in various settings (urban, rural)? | 82 | 100 | 75 | 73.33333333333333 | 60 | 100 | 81.66666666666666 | 78.54127870887648
 |  |  | Conduct social marketing research to improve acceptability of zinc supplementation – packaging, language, health messages | 81 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0.5 | 0 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Conduct social marketing research to improve acceptability of zinc supplementation – packaging, language, health messages | 83 | 96.66666666666667 | 77.77777777777779 | 80 | 46.66666666666666 | 100 | 80.22222222222223 | 75.15001034554106
 |  |  | Assess effectiveness of delivery strategies to provide zinc and ORT | 82 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0 | 0 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Assess effectiveness of delivery strategies to provide zinc and ORT | 84 | 96.66666666666667 | 75 | 80 | 66.66666666666666 | 100 | 83.66666666666667 | 81.22284295468653
 |  |  | Assess optimal dose and duration of zinc for diarrhoea treatment | 83 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | Assess optimal dose and duration of zinc for diarrhoea treatment | 85 | 100 | 83.33333333333334 | 93.33333333333333 | 53.33333333333334 | 90 | 84 | 79.32340161390441
 |  |  | Assess integration of zinc treatment for diarrhoea and zinc in prevention | 84 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 0.5 | 0.5 | 0.5 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | Assess integration of zinc treatment for diarrhoea and zinc in prevention | 86 | 83.33333333333334 | 83.33333333333334 | 100 | 73.33333333333333 | 80 | 84 | 82.27188081936686
 |  |  | Identify group(s) at risk of not receiving zinc therapy | 85 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | 0.5 | 0.5 | 1 | 1 | 0.5 |  | 1 | 0.5 | 1 | 1 | 0 |  | 1 | 0 | 1 | 0.5 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Identify group(s) at risk of not receiving zinc therapy | 87 | 100 | 70 | 95.83333333333334 | 43.33333333333334 | 100 | 81.83333333333334 | 76.03817504655494
 |  |  | Identify formulation that increases acceptability of zinc (less adverse events) | 86 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 |  | 1 | 0 | 0 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Identify formulation that increases acceptability of zinc (less adverse events) | 88 | 93.33333333333333 | 71.875 | 93.33333333333333 | 50 | 100 | 81.70833333333333 | 76.90487274984481
 |  | Promotion of breastfeeding | Design and test interventions addressing barriers to promotion of breastfeeding in BFHI hospitals. | 87 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 0.5 | 0.5 |  | 1 | 0 | 1 | 1 | 1 |  | 0.5 | 0.5 | 1 | 1 |  | 1 | 0.5 | 1 | 1 |  | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0.5 | 0.5 |  | Design and test interventions addressing barriers to promotion of breastfeeding in BFHI hospitals. | 89 | 96.66666666666667 | 80 | 70.83333333333334 | 73.33333333333333 | 66.66666666666666 | 77.5 | 77.028243327126
 |  |  | Design and test interventions addressing barriers to promotion of prolonged breastfeeding – community support? Local health system support? Peer group support? Mother to mother? | 88 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Design and test interventions addressing barriers to promotion of prolonged breastfeeding – community support? Local health system support? Peer group support? Mother to mother? | 90 | 83.33333333333334 | 88.88888888888889 | 66.66666666666666 | 76.66666666666667 | 93.33333333333333 | 81.77777777777777 | 80.98282640182082
 |  |  | Determine which methods is most cost-effective and sustainable for promotion of EBF and continued breastfeeding till 24 months of age | 89 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Determine which methods is most cost-effective and sustainable for promotion of EBF and continued breastfeeding till 24 months of age | 91 | 93.33333333333333 | 63.88888888888889 | 66.66666666666666 | 73.33333333333333 | 93.33333333333333 | 78.11111111111111 | 77.68052969170286
 |  |  | What is the effect of nutrition couseling training of health workers on breastfeeding indicators (exclusivity, duration, etc)? | 90 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | What is the effect of nutrition couseling training of health workers on breastfeeding indicators (exclusivity, duration, etc)? | 92 | 96.66666666666667 | 80.55555555555556 | 70 | 36.66666666666666 | 80 | 72.77777777777779 | 67.28946823918892
 |  |  | Identify means to make breastfeeding promotion by community sustainable | 91 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Identify means to make breastfeeding promotion by community sustainable | 93 | 96.66666666666667 | 80.55555555555556 | 76.66666666666667 | 70 | 93.33333333333333 | 83.44444444444444 | 81.5166563211256
 | Research to improve affordability of existing interventions | Zinc supplementation | What is the acceptability/usage of different zinc formulations and relationship with cost? | 92 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 |  | 0.5 | 0.5 | 0 | 1 | 0 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | What is the acceptability/usage of different zinc formulations and relationship with cost? | 94 | 96.66666666666667 | 58.82352941176471 | 66.66666666666666 | 50 | 96.66666666666667 | 73.76470588235294 | 70.42611457991016
 |  |  | Zinc at a cost vs. given free: which is more acceptable, and sustainable in developing country context? | 93 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 |  | 0.5 | 0 | 0 | 1 | 0 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |  | Zinc at a cost vs. given free: which is more acceptable, and sustainable in developing country context? | 95 | 90 | 61.76470588235294 | 73.33333333333333 | 43.33333333333334 | 90 | 71.68627450980391 | 67.5079417241757
 |  |  | Effectiveness, HPSR and educational /behaviour modification studies to improve the deliverability /cost of Zn treatment in diarrhoea control programmes in several regions of the world with different epidemiological profiles. | 94 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 1 | 1 |  | Effectiveness, HPSR and educational /behaviour modification studies to improve the deliverability /cost of Zn treatment in diarrhoea control programmes in several regions of the world with different epidemiological profiles. | 96 | 96.66666666666667 | 80.55555555555556 | 73.33333333333333 | 40 | 76.66666666666667 | 73.44444444444444 | 68.36333540244154
 |  |  | Efficacy, effectiveness and cost studies that will increase the utilization of Zn food fortification programs in developing countries. | 95 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0 |  | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 0 | 1 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | Efficacy, effectiveness and cost studies that will increase the utilization of Zn food fortification programs in developing countries. | 97 | 93.33333333333333 | 55.88235294117647 | 73.33333333333333 | 16.66666666666666 | 93.33333333333333 | 66.50980392156863 | 59.03640413334794
 |  | Dysentery | Clinical trials to compare the efficacy of different available low cost drugs for the management of shigellosis | 96 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 |  | 0.5 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0.5 | 1 | 1 |  | 1 | 1 | 0.5 | 1 |  | 1 | 0.5 | 1 | 1 |  | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Clinical trials to compare the efficacy of different available low cost drugs for the management of shigellosis | 98 | 100 | 67.64705882352942 | 83.33333333333334 | 10 | 100 | 72.19607843137256 | 62.72684120203017
 |  |  | Define ways to reduce duration of therapy, incluiding single-dose therapy, through selection of appropriate agents | 97 | 0 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 |  | 1 | 1 | 1 | 0.5 | 1 |  | 0.5 | 1 | 1 | 0 | 0 |  | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Define ways to reduce duration of therapy, incluiding single-dose therapy, through selection of appropriate agents | 99 | 83.33333333333334 | 76.66666666666667 | 83.33333333333334 | 26.66666666666667 | 100 | 74 | 66.62321539416511
 |  | Water and Sanitation | System and community research to reduce costs /improve deliverability and increase coverage of piped water systems (Impact on morbidity and mortality) | 98 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 0.5 |  | 0.5 | 0 | 1 | 0.5 |  | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 |  | System and community research to reduce costs /improve deliverability and increase coverage of piped water systems (Impact on morbidity and mortality) | 100 | 76.66666666666667 | 75 | 76.66666666666667 | 23.33333333333333 | 73.33333333333333 | 65.00000000000001 | 58.45437616387338
 |  |  | Develop simple methods for purification of water at point of use | 99 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | 1 | 0 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0 | 0.5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 |  | Develop simple methods for purification of water at point of use | 101 | 93.33333333333333 | 82.35294117647058 | 63.33333333333333 | 43.33333333333334 | 90 | 74.47058823529412 | 69.74367400591521
 |  |  | Research to develop new ways of sewage treatment systems that will make them affordable to developing countries | 100 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0 |  | 0.5 | 0 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 0 | 1 | 0 | 0.5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | Research to develop new ways of sewage treatment systems that will make them affordable to developing countries | 102 | 80 | 70.58823529411765 | 60 | 36.66666666666666 | 93.33333333333333 | 68.11764705882352 | 63.31580676963522
 |  | Cholera vaccine | Effectiveness studies (impact on morbidity and mortality) and studies to reduce the cost and/or improve deliverability of cholera vaccines in high burden countries . | 101 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 |  | 1 | 1 | 0.5 | 0.5 | 1 |  | 1 |  | 1 | 0.5 | 0 |  | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0.5 |  | Effectiveness studies (impact on morbidity and mortality) and studies to reduce the cost and/or improve deliverability of cholera vaccines in high burden countries . | 103 | 83.33333333333334 | 75 | 70 | 0 | 80 | 61.66666666666667 | 52.06703910614525
 |  | Nutrition | Cash transfer programs to improve diet quality and nutrition in poor areas (impact on morbidity and mortality). | 102 | 0 | 1 | 0 | 0.5 | 0 | 0.5 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 0.5 |  | 1 | 0.5 | 1 | 0 | 0.5 | 0 | 1 |  | 0.5 | 0 | 0 | 0 | 0.5 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0.5 | 0 | 1 | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | Cash transfer programs to improve diet quality and nutrition in poor areas (impact on morbidity and mortality). | 104 | 53.33333333333334 | 37.5 | 63.33333333333333 | 26.66666666666667 | 80 | 52.16666666666667 | 48.28367473618871
 | Research to improve sustainability of existing interventions | Sustaining zinc supplementation | Testing of locally adapted health messages to promote zinc and to explain zinc to mothers/users | 103 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Testing of locally adapted health messages to promote zinc and to explain zinc to mothers/users | 105 | 86.66666666666667 | 80.55555555555556 | 100 | 40 | 100 | 81.44444444444444 | 74.94930684874818
 |  | Breastfeeding promotion | Testing strategies to strengthen linkage of public sector and non-government groups in promoting breastfeeding and implementing breastfeeding programs | 104 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | Testing strategies to strengthen linkage of public sector and non-government groups in promoting breastfeeding and implementing breastfeeding programs | 106 | 90 | 72.22222222222221 | 76.66666666666667 | 70 | 83.33333333333334 | 78.44444444444446 | 77.29567556383199
 |  | Water and Sanitation | Implementation of point-of-use treatment and water storage practices. | 105 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |  | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0 |  | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |  | Implementation of point-of-use treatment and water storage practices. | 107 | 96.66666666666667 | 71.875 | 56.66666666666666 | 53.33333333333334 | 93.33333333333333 | 74.375 | 71.38035381750467
 |  |  | Research to improve deliverability, measure effectiveness and sustainability of Fly control interventions (impact on morbidity and mortality). | 106 | 1 | 1 | 0 | 0.5 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0.5 |  | 1 | 1 | 0 | 0 | 0.5 |  | 0 | 1 | 0 | 0 | 0 |  |  | 1 | 0.5 | 0.5 | 0 |  | 1 | 1 | 0.5 | 1 |  | 1 | 0.5 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 |  | Research to improve deliverability, measure effectiveness and sustainability of Fly control interventions (impact on morbidity and mortality). | 108 | 63.33333333333333 | 28.57142857142857 | 54.16666666666666 | 0 | 66.66666666666666 | 42.54761904761904 | 36.17251928704442
 |  | Nutrition | Policy, systems and education /behaviour modification research to improve current strategies aiming to improve diet quality of family in areas with low access to good diets (impact on morbidity and mortality). | 107 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 0.5 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 |  | Policy, systems and education /behaviour modification research to improve current strategies aiming to improve diet quality of family in areas with low access to good diets (impact on morbidity and mortality). | 109 | 93.33333333333333 | 63.88888888888889 | 66.66666666666666 | 53.33333333333334 | 80 | 71.44444444444444 | 68.9033726463894
 |  | General | What are the attributes of sustainable programmes? | 108 | 0 | 0.5 | 0.5 | 0.5 | 1 | 0 | 0.5 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 |  | 0.5 | 1 |  |  |  |  | 0.5 | 1 |  |  |  |  | 1 | 0 |  |  |  |  | 1 |  | 0.5 | 1 |  | 1 |  | 0.5 | 1 |  | 1 |  | 0.5 | 1 | 0 |  | 1 | 1 | 0.5 | 0 |  | 0 | 0 | 0 | 0 |  | 0 | 0 | 0 | 0.5 | 0.5 | 1 | 1 | 0 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 |  | What are the attributes of sustainable programmes? | 110 | 60 | 66.66666666666666 | 83.33333333333334 | 20.83333333333334 | 73.33333333333333 | 60.83333333333334 | 54.43047796399751
Research for development of new interventions | Basic research | Emerging new pathogens | Develop molecular techniques for identifying [elucidating] new pathogens causing diarrhoea | 109 | 1 | 1 | 0.5 | 0 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0 | 1 | 1 | 0.5 | 0 | 1 | 0 | 0.5 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |  | Develop molecular techniques for identifying [elucidating] new pathogens causing diarrhoea | 111 | 70 | 52.77777777777778 | 45.83333333333333 | 0 | 50 | 43.72222222222221 | 37.03548520587627
 |  | Dysentery | Study capacity of Shigella to re-programme invaded epithelial cells to produce pro-inflammatory mediators. | 110 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0 | 0 |  | 1 | 1 | 0.5 | 0 | 0 |  | 1 | 1 | 1 | 0 | 0 |  |  | 1 | 0 | 0 | 0.5 |  | 1 | 0 | 0 | 1 |  | 1 | 0 | 0 | 0 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0.5 | 0.5 | 0 |  | Study capacity of Shigella to re-programme invaded epithelial cells to produce pro-inflammatory mediators. | 112 | 76.66666666666667 | 50 | 37.5 | 0 | 56.66666666666666 | 44.16666666666667 | 37.5310366232154
 |  |  | Assess the efficacy of zinc supplementation as adjunct to standard anti-Shigella treatment on the gut mucosal and systemic response | 111 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 |  | 1 | 1 | 0.5 | 0 | 1 |  | 1 | 1 | 0.5 | 0 | 0 |  | 0.5 | 1 | 0 | 0.5 | 1 |  | 1 | 1 | 0.5 | 1 |  | 1 | 0 | 0.5 | 0.5 |  | 0 | 0.5 | 1 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | Assess the efficacy of zinc supplementation as adjunct to standard anti-Shigella treatment on the gut mucosal and systemic response | 113 | 100 | 60 | 54.16666666666666 | 20 | 93.33333333333333 | 65.5 | 58.79733085040348
 |  |  | Test the immunogenicity of the new generation of vaccine against Shigella | 112 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 |  | 0.5 | 0.5 | 1 |  | 1 | 1 | 0.5 | 0.5 | 1 |  | 1 |  | 0 | 0 | 0 |  | 1 | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 0.5 |  | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 0.5 | 1 | 1 | 1 |  | 0.5 | 1 |  | Test the immunogenicity of the new generation of vaccine against Shigella | 114 | 100 | 61.53846153846154 | 45.83333333333333 | 10 | 91.66666666666666 | 61.80769230769231 | 54.12130544812109
 |  |  | Identify and define the roles of anti-inflammatory agents in the management of shigellosis and other invasive diarrhoeas | 113 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0 | 1 |  | 1 | 1 | 0.5 | 0 | 1 |  | 1 |  | 0 | 0 | 0 |  |  | 1 | 0 | 1 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 0 | 1 | 0.5 |  | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0.5 | 0 |  | Identify and define the roles of anti-inflammatory agents in the management of shigellosis and other invasive diarrhoeas | 115 | 76.66666666666667 | 53.84615384615385 | 79.16666666666666 | 3.333333333333333 | 56.66666666666666 | 53.93589743589744 | 46.13892470037722
 |  |  | Find practical ways to foster secretion of antibacterial peptides as a new therapy | 114 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 |  | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 |  |  | 1 | 0.5 | 0 | 1 |  |  |  | 0 | 0 | 0 |  |  | 1 | 0 | 0.5 | 0.5 |  | 0.5 | 0 | 0.5 | 1 |  | 0.5 | 0 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0.5 | 0 | 1 | 0.5 | 0 |  | Find practical ways to foster secretion of antibacterial peptides as a new therapy | 116 | 57.14285714285714 | 45.45454545454545 | 33.33333333333333 | 3.333333333333333 | 53.33333333333334 | 38.51948051948052 | 33.14364716599353
 |  |  | Develop and test the efficacy of rapid diagnostic test to determine Shigella infection | 115 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 0.5 |  | 1 | 1 | 0 | 0.5 | 0.5 |  | 1 |  | 0 | 0 | 0 |  | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 0.5 | 0 |  | Develop and test the efficacy of rapid diagnostic test to determine Shigella infection | 117 | 100 | 42.85714285714285 | 63.33333333333333 | 10 | 73.33333333333333 | 57.90476190476191 | 50.92311785049215
 |  | Diarrhoea | Study the capacity of Cryptosporidium to invade epithelial cells and its impact on the mucosal immune response | 116 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0.5 |  | 1 | 1 | 0 | 0 | 0.5 |  | 1 |  | 0 | 0 | 0 |  | 0.5 | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0 | 0 | 0.5 | 0 | 0.5 | 0.5 | 0 |  | Study the capacity of Cryptosporidium to invade epithelial cells and its impact on the mucosal immune response | 118 | 76.66666666666667 | 32.14285714285715 | 45.83333333333333 | 0 | 46.66666666666666 | 40.26190476190477 | 34.35776358960717
 |  |  | Develop new anti-secretory drugs (i.e. enkephalinase inhibitors, and anti CFTR) | 117 | 1 | 1 | 0 | 0.5 | 0 | 1 | 1 | 0 | 0.5 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 |  |  | 1 | 0.5 | 0 | 1 |  |  |  | 0 | 0 | 1 |  |  | 1 | 0 | 0.5 | 0.5 |  | 1 | 0 | 0.5 | 0.5 |  | 1 | 0 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0 | 0 | 0.5 | 0 | 0.5 | 0.5 | 0 |  | Develop new anti-secretory drugs (i.e. enkephalinase inhibitors, and anti CFTR) | 119 | 60 | 54.54545454545454 | 37.5 | 0 | 43.33333333333334 | 39.07575757575758 | 33.02000451441792
 |  |  | Study the pathogenic mechanisms of diarrhoea caused by viruses other than rotavirus. | 118 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0 | 0.5 |  | 1 | 1 | 0.5 | 0 | 0.5 |  | 0.5 |  | 0.5 | 0 | 0 |  | 1 | 1 | 0 | 0.5 | 1 |  | 1 | 1 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |  | 1 | 1 | 1 | 1 |  | 1 | 0.5 | 1 | 1 |  | 1 | 0.5 | 0 |  | Study the pathogenic mechanisms of diarrhoea caused by viruses other than rotavirus. | 120 | 76.66666666666667 | 42.85714285714285 | 58.33333333333334 | 0 | 83.33333333333334 | 52.23809523809524 | 44.35887204043629
 |  |  | Develop and test the efficacy of rapid diagnostic test to identify pathogens causing [determine] infection | 119 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 |  | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 1 |  |  | 1 | 0 | 0 | 1 |  |  |  | 0.5 | 0 | 1 |  | 1 | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0.5 | 0.5 | 1 |  | 0 | 0 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0 |  | Develop and test the efficacy of rapid diagnostic test to identify pathogens causing [determine] infection | 121 | 85.71428571428571 | 54.16666666666666 | 54.16666666666666 | 13.33333333333333 | 70 | 55.47619047619048 | 49.18262835860601
 |  | New vaccines | Develop and test ETEC vaccines | 120 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 1 |  | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 |  | 1 | 1 | 0.5 | 0.5 | 1 |  | 0.5 |  | 1 | 0 | 0 |  |  | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0.5 |  | Develop and test ETEC vaccines | 122 | 78.57142857142857 | 65.38461538461539 | 70 | 0 | 83.33333333333334 | 59.45787545787546 | 50.24072141390578
 |  |  | Develop and test norovirus vaccines | 121 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 1 |  | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 0 | 1 |  |  | 0.5 | 0.5 | 0 | 1 |  |  |  | 1 | 0 | 0 |  |  | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 0 |  | Develop and test norovirus vaccines | 123 | 78.57142857142857 | 45.45454545454545 | 60 | 0 | 80 | 52.80519480519481 | 44.82671890493119
 |  |  | Develop and test Shigella vaccines | 122 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 |  | 1 | 1 | 1 | 0.5 | 1 |  | 0.5 |  | 1 | 0 | 0 |  | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0 | 0.5 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.5 | 1 |  | Develop and test Shigella vaccines | 124 | 89.28571428571429 | 75 | 70 | 20 | 86.66666666666667 | 68.19047619047619 | 60.77857586237475
 |  |  | Develop and test Campylobacter vaccines | 123 | 1 | 1 | 0 | 0.5 | 0 | 1 | 0.5 | 0 |  | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0.5 | 1 |  |  | 0 | 0 | 0.5 | 1 |  |  |  | 1 | 0 | 0 |  |  | 0 | 1 | 0.5 | 0.5 |  | 0 | 0 | 0.5 | 1 |  | 0 | 0.5 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0 | 0 | 1 | 0 | 1 | 0.5 | 0 | 1 | 0.5 | 0.5 |  | Develop and test Campylobacter vaccines | 125 | 57.14285714285714 | 36.36363636363637 | 29.16666666666667 | 0 | 53.33333333333334 | 35.2012987012987 | 29.91090070699009
 |  |  | Develop and test EPEC vaccines | 124 | 1 | 1 | 0 | 0.5 | 0 | 1 | 0.5 | 0 |  | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 |  |  | 1 | 1 | 0.5 | 1 |  |  |  | 1 | 0 | 0 |  |  | 0.5 | 1 | 0.5 | 0.5 |  | 0.5 | 0 | 0.5 | 1 |  | 0.5 | 0.5 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0.5 | 0.5 |  | Develop and test EPEC vaccines | 126 | 57.14285714285714 | 72.72727272727273 | 41.66666666666667 | 0 | 60 | 46.30735930735931 | 38.93592751134651
 |  |  | Develop and test H. pylori vaccines | 125 | 1 | 1 | 0.5 | 0.5 | 0 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 0 | 0 | 0 | 0 |  |  | 0 | 0 | 0 | 0 |  |  |  | 1 | 0 | 0.5 |  |  | 0 | 1 | 0.5 | 1 | 1 | 0 | 0 | 0.5 | 1 | 1 | 0 | 0.5 | 0.5 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0 | 1 | 0.5 | 0 | 0.5 | 0 | 0 |  | Develop and test H. pylori vaccines | 127 | 70 | 9.090909090909092 | 46.66666666666666 | 0 | 46.66666666666666 | 34.48484848484848 | 29.61232436092771
 |  |  | Develop and test vaccines for E. histolytica | 126 | 1 | 1 | 0 | 0.5 | 0 | 1 | 0.5 | 0 |  | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |  |  | 0 | 0 | 0 | 0 |  | 0.5 |  | 1 | 0 | 0.5 |  |  | 0.5 | 1 | 0.5 | 1 |  | 0.5 | 0 | 0.5 | 1 |  | 0.5 | 0.5 | 0.5 | 0.5 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0.5 | 1 | 0.5 | 0 | 1 | 0 | 0.5 |  | Develop and test vaccines for E. histolytica | 128 | 57.14285714285714 | 12.5 | 45.83333333333333 | 0 | 56.66666666666666 | 34.42857142857143 | 29.41628979338476
 |  |  | Develop and test new [NAME] vaccines that will be heat-stable and able to immunize newborns | 127 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 |  | 1 | 0 | 0 | 1 |  | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | Develop and test new [NAME] vaccines that will be heat-stable and able to immunize newborns | 129 | 96.42857142857143 | 68.75 | 80 | 30 | 96.66666666666667 | 74.36904761904762 | 67.66538086370487
 |  | Zinc supplementation | Develop the technology to deliver Zn to children using prolong dosing intervals | 128 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0.5 | 0 | 1 | 1 | 0 | 0.5 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | Develop the technology to deliver Zn to children using prolong dosing intervals | 130 | 100 | 61.11111111111111 | 50 | 40 | 96.66666666666667 | 69.55555555555556 | 65.36726670804883
 |  |  | Study the effect of zinc on the gut secretory mechanisms | 129 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0.5 | 1 | 1 | 0 | 0 | 0 |  | 1 | 1 | 0 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 0 |  | Study the effect of zinc on the gut secretory mechanisms | 131 | 80 | 41.17647058823529 | 50 | 6.666666666666667 | 66.66666666666666 | 48.90196078431372 | 42.65271844305692
 |  |  | Study the effect of zinc on the innate and adaptative immunity | 130 | 1 | 0.5 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 0 | 0.5 | 1 | 1 | 0.5 | 0 | 0 |  | 1 | 1 | 0.5 | 0 | 0.5 | 0.5 | 0 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0 |  | Study the effect of zinc on the innate and adaptative immunity | 132 | 70 | 44.11764705882353 | 60 | 30 | 63.33333333333333 | 53.49019607843137 | 50.03249717019024
 |  | Probiotics | Study the effect of probiotics on the mucosal and systemic  immune response. | 131 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 |  | 1 | 1 | 0.5 | 0 | 1 |  | 1 | 1 | 0.5 | 0 | 1 |  | 0.5 | 1 | 0 | 1 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 1 | 1 |  | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 0.5 | 0 |  | Study the effect of probiotics on the mucosal and systemic  immune response. | 133 | 86.66666666666667 | 66.66666666666666 | 66.66666666666666 | 10 | 70 | 60 | 52.34016139044072
 |  |  | Determine the colonization of different probiotics in human gut | 132 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |  | 1 | 1 | 0 | 0 | 1 |  | 1 | 0 | 1 | 0 | 1 |  | 1 | 1 | 0 | 1 | 0.5 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 1 | 0.5 |  | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 0 | 0.5 | 0 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0.5 | 0 |  | Determine the colonization of different probiotics in human gut | 134 | 86.66666666666667 | 60 | 58.33333333333334 | 13.33333333333333 | 40 | 51.66666666666667 | 45.89385474860336
 |  | Nutrition | Study the effect of short chain fatty acids on the mucosal secretory mechanisms | 133 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 0 |  | 0 | 1 | 0.5 | 0 | 0 |  | 0 | 1 | 0.5 | 0 | 0.5 |  | 0 | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 |  | Study the effect of short chain fatty acids on the mucosal secretory mechanisms | 135 | 86.66666666666667 | 30 | 75 | 0 | 76.66666666666667 | 53.66666666666667 | 45.72004965859715
 | Clinical research | ORS formulation | What is the acceptability of the new ORS in both urban and rural setting? | 134 | 1 | 1 | 1 | 0.5 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |  | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | What is the acceptability of the new ORS in both urban and rural setting? | 136 | 96.42857142857143 | 67.64705882352942 | 100 | 36.66666666666666 | 100 | 80.1484593837535 | 73.54088749093678
 |  |  | Use of new ORS formulation and effect on breastfeeding, other milk feeding, fluid intake | 135 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 0 | 0.5 | 1 | 0 |  | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Use of new ORS formulation and effect on breastfeeding, other milk feeding, fluid intake | 137 | 96.66666666666667 | 55.88235294117647 | 86.66666666666667 | 13.33333333333333 | 100 | 70.50980392156865 | 61.88556614452113
 |  |  | Identify barriers against promotion of reduced-osmolarity ORS in country programmes | 136 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0.5 |  | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 |  | Identify barriers against promotion of reduced-osmolarity ORS in country programmes | 138 | 96.66666666666667 | 73.52941176470588 | 100 | 40 | 90 | 80.0392156862745 | 73.91718698652645
 |  | Zinc supplementation | Clinical trials to evaluate the efficacy of different doses of zinc in the treatment of diarrhoea: stool output, duration, markers of inflammation | 137 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | Clinical trials to evaluate the efficacy of different doses of zinc in the treatment of diarrhoea: stool output, duration, markers of inflammation | 139 | 100 | 77.77777777777779 | 90 | 53.33333333333334 | 80 | 80.22222222222221 | 76.18663356093525
 |  |  | Clinical trials to evaluate the efficacy of zinc in the treatment of diarrhoea due to different pathogens, i.e. rotavirus, cholera, ETEC, etc. | 138 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |  | Clinical trials to evaluate the efficacy of zinc in the treatment of diarrhoea due to different pathogens, i.e. rotavirus, cholera, ETEC, etc. | 140 | 86.66666666666667 | 75 | 93.33333333333333 | 40 | 66.66666666666666 | 72.33333333333333 | 67.30602110490378
 |  | Rotavirus vaccine | Community-based rotavirus vaccine trials | 139 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 |  | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0.5 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 |  | Community-based rotavirus vaccine trials | 141 | 93.33333333333333 | 94.11764705882352 | 70 | 36.66666666666666 | 93.33333333333333 | 77.49019607843137 | 71.12498630737211
 |  |  | Impact of rotavirus vaccine on incidence of acute diarrhoeas | 140 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 |  | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 |  | Impact of rotavirus vaccine on incidence of acute diarrhoeas | 142 | 100 | 88.23529411764706 | 83.33333333333334 | 50 | 90 | 82.31372549019609 | 77.36480812064119
 |  |  | Cost-effectiveness of rotavirus vaccine | 141 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 |  | 1 | 0 | 1 | 0.5 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 |  | Cost-effectiveness of rotavirus vaccine | 143 | 100 | 73.52941176470588 | 76.66666666666667 | 33.33333333333333 | 96.66666666666667 | 76.0392156862745 | 69.60309635958666
 |  | Drug therapy for diarrhoea | Clinical trials to evaluate the efficacy and safety of anti-secretory drugs given along with ORS and zinc supplementation on diarrhoeal stool output | 142 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | 1 | 0 | 1 | 1 | 0.5 |  |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0 | 1 | 0 | 0.5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 1 | 0 | 0.5 | 0 | 1 | 0.5 | 0.5 |  | Clinical trials to evaluate the efficacy and safety of anti-secretory drugs given along with ORS and zinc supplementation on diarrhoeal stool output | 144 | 66.66666666666666 | 75 | 66.66666666666666 | 23.33333333333333 | 60 | 58.33333333333333 | 52.74984481688392
 |  |  | Conduct trials to evaluate the efficacy of pre- and pro-biotics for on the clinical outcome of diarrhoea | 143 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 |  | 1 | 1 | 0.5 | 0 | 1 |  | 1 | 1 | 0.5 | 0 | 1 |  | 0.5 | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0.5 | 1 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0.5 | 0 |  | Conduct trials to evaluate the efficacy of pre- and pro-biotics for on the clinical outcome of diarrhoea | 145 | 86.66666666666667 | 73.33333333333333 | 75 | 20 | 50 | 61 | 54.65859714463066
 |  |  | Conduct trials to evaluate the efficacy of pre- and pro-biotics for given along ORS and zinc on the clinical outcome of diarrhoea | 144 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 1 |  | 1 |  | 0.5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0 | 1 | 1 |  | 1 | 0.5 | 1 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0.5 | 0 |  | Conduct trials to evaluate the efficacy of pre- and pro-biotics for given along ORS and zinc on the clinical outcome of diarrhoea | 146 | 76.66666666666667 | 56.25 | 75 | 20 | 50 | 55.58333333333334 | 50.13500931098697
 |  |  | Develop and test new antibiotics for the management of Shigella dysentery | 145 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 |  | 1 | 1 | 0.5 | 0 | 1 |  | 1 |  | 1 | 0 | 1 |  | 1 | 1 | 0 | 0.5 | 0.5 |  | 1 | 0 | 0.5 | 0.5 |  | 1 | 0.5 | 0.5 | 0.5 |  | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 0.5 | 0 | 0.5 | 1 | 1 | 0.5 | 0.5 |  | Develop and test new antibiotics for the management of Shigella dysentery | 147 | 96.66666666666667 | 78.57142857142857 | 41.66666666666667 | 13.33333333333333 | 76.66666666666667 | 61.38095238095239 | 54.10703201205995
 |  |  | Clinical trials to evaluate the efficacy and effectiveness of the new anti-cryptosporidial drugs/agents. | 146 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 |  | 1 | 1 | 0 | 0 | 1 |  | 1 | 1 | 1 | 0 | 0 |  | 1 | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0 | 0 | 0.5 | 0.5 | 1 | 0.5 | 0 |  | Clinical trials to evaluate the efficacy and effectiveness of the new anti-cryptosporidial drugs/agents. | 148 | 100 | 63.33333333333333 | 50 | 0 | 56.66666666666666 | 54 | 45.90937306021105
 |  |  | Develop and test new antibiotics for the management of cholera | 147 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 0 | 1 | 0.5 | 1 |  | 1 | 0 | 0 | 0.5 | 1 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0 | 0.5 | 1 | 0.5 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 0.5 | 0 | 1 | 0 | 1 | 0.5 | 0.5 |  | Develop and test new antibiotics for the management of cholera | 149 | 86.66666666666667 | 67.64705882352942 | 53.33333333333334 | 6.666666666666667 | 60 | 54.86274509803921 | 47.50648117720086
 |  | Nutrition | Clinical trials to evaluate the efficacy of short chain fatty acids [or its precursors] mixed with ORS and zinc supplementation on stool output in cholera and acute non-cholera diarrhoea | 148 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0 | 0.5 |  | 1 | 1 | 0.5 | 0 | 0.5 |  | 1 |  | 0.5 | 0 | 0 |  |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 0.5 | 1 |  | 1 | 0 | 1 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | Clinical trials to evaluate the efficacy of short chain fatty acids [or its precursors] mixed with ORS and zinc supplementation on stool output in cholera and acute non-cholera diarrhoea | 150 | 86.66666666666667 | 42.30769230769231 | 50 | 16.66666666666666 | 100 | 59.12820512820512 | 52.93319963711025
 | Public health research | Zinc supplementation | Assess effectiveness of programmes introducing ORS and zinc in the treatment of diarrhoea in the community on cost of treatment, access to treatment, ORS use rates, antimicrobial use rates, hospital visits for subsequent morbidity, case fatality rates, physician prescription rates. | 149 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 |  | 1 | 1 | 1 | 0.5 | 1 |  | 1 | 1 | 1 | 0 | 0 |  | 0.5 | 1 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0.5 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |  | Assess effectiveness of programmes introducing ORS and zinc in the treatment of diarrhoea in the community on cost of treatment, access to treatment, ORS use rates, antimicrobial use rates, hospital visits for subsequent morbidity, case fatality rates, physician prescription rates. | 151 | 100 | 76.66666666666667 | 63.33333333333333 | 50 | 93.33333333333333 | 76.66666666666666 | 72.76225946617008
 |  | Integrating new vaccines in current public health set-up | Testing different rotavirus vaccination schedule | 150 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 1 | 0 | 1 | 1 | 0 | 0.5 | 0 | 1 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 | 1 | 0.5 |  | Testing different rotavirus vaccination schedule | 152 | 86.66666666666667 | 69.44444444444444 | 76.66666666666667 | 26.66666666666667 | 93.33333333333333 | 70.55555555555556 | 63.82785019656529
 |  |  | Document impact of the new vaccine (including rotavirus vaccine) after introduction in the community and in various delivery systems | 151 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 | 1 | 1 | 0 | 0.5 | 1 | 1 |  | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 1 | 0.5 | 1 | 1 | 1 | 0 | 0.5 | 0.5 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | Document impact of the new vaccine (including rotavirus vaccine) after introduction in the community and in various delivery systems | 153 | 100 | 58.82352941176471 | 70 | 33.33333333333333 | 96.66666666666667 | 71.76470588235294 | 66.14306057618579
 |  | Nutrition | Solar ovens to keep weaning foods above >50C for a day | 152 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 0 | 0.5 | 0.5 |  | 0.5 | 0.5 | 0 | 0.5 | 0.5 |  |  | 0 | 0 | 0 | 0 |  | 0.5 | 0 |  | 1 |  | 0.5 | 0 |  | 1 |  | 0.5 | 0 |  | 0.5 |  | 1 | 0 | 1 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | Solar ovens to keep weaning foods above >50C for a day | 154 | 80 | 21.42857142857143 | 44.44444444444444 | 16.66666666666666 | 90 | 50.50793650793651 | 45.78227069847182
 |  |  | Low cost no electrical/no fuel consuming refrigerators to storage food at home level. | 153 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |  | 0 | 1 | 1 | 1 | 1 | 1 | 0.5 | 0.5 | 0.5 |  |  | 1 | 0.5 | 0.5 | 0 |  | 0.5 | 1 |  | 0 | 0 |  | 0 | 0 | 0.5 | 0.5 |  | 1 | 0.5 | 0.5 | 0 |  | 1 | 0.5 | 0.5 | 1 |  | 1 | 0.5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |  | Low cost no electrical/no fuel consuming refrigerators to storage food at home level. | 155 | 78.57142857142857 | 38.46153846153847 | 62.5 | 20 | 96.66666666666667 | 59.23992673992674 | 53.46315850505795
 |  |  | Develop interventions that will reduce bacterial contamination of crops irrigated with contaminated water in developing countries | 154 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |  | 0 | 1 | 1 | 0 | 1 | 1 | 0.5 | 0.5 | 0.5 |  | 0.5 | 1 | 0.5 | 0 | 0.5 |  | 0.5 | 1 |  | 0.5 | 0 |  | 0 |  | 0.5 | 1 |  | 0.5 |  | 0.5 | 1 |  | 1 |  | 0.5 | 0.5 |  | 0 |  | 1 | 0 | 1 | 0 | 0.5 | 1 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.5 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |  | Develop interventions that will reduce bacterial contamination of crops irrigated with contaminated water in developing countries | 156 | 64.28571428571429 | 46.15384615384615 | 61.11111111111111 | 26.66666666666667 | 76.66666666666667 | 54.97680097680097 | 50.69437907426734